Emma Andrus

A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique histopathology and complications

Timothy Caulfield, JD, discusses the sessions he's most looking forward to at this year's Society for Pediatric Dermatology annual meeting, including his talk on overcoming misinformation in pediatric dermatology.

Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.

Investigators explored the genetic relationship between psoriatic disease and serum lipid levels.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

The most common conditions or concerns patients with atopic dermatitis (AD) reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

Investigators found a steady reduction of immunoglobulin E (IgE) levels in patients regardless of dupilumab dosing interval.

According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.

Researchers conducted systematic mapping of relevant digital health intervention literature to determine the impact of these interventions on dermatologic care outcomes.

Matthew Mansh, MD, FAAD, discusses inequities faced by transgender and gender-diverse patient populations.

Scientists have found a new therapy for the severe inflammatory skin disorder.

The approval makes the drug Europe’s first and only interleukin (IL)-17A inhibitor approved for the condition.